Angitia secures $130M Series D to develop next-generation bone therapies
What’s the deal? Angitia Biopharmaceuticals has raised $130M in a Series D round to advance a pipeline of bispecific antibodies for bone disease and metabolic disorders. The company is targeting pathways linked to bone growth, an area where large drugmakers such as Amgen are also active.
The round was co-led by Frazier Life SciencesDealroom has a profile for this one. Try Dealroom → and Venrock Healthcare Capital Partners, according to Angitia. The financing will help fund mid-stage clinical development and support multiple programmes moving through trials.
Why now? Angitia is entering a more expensive phase of drug development, where clinical studies expand in size and timelines stretch. Fresh capital is often critical at this stage, especially for companies aiming to compete in established therapeutic markets.
Bone-building therapies have become a renewed focus as companies search for new options beyond existing osteoporosis treatments. Angitia is positioning its candidates as potential next-generation approaches in that space.
What could go wrong? Mid-stage trials remain a major hurdle, with many programmes failing to show clear efficacy or clean safety profiles. Bispecific antibodies can also be harder to manufacture and dose, raising execution risk.
Competition is another challenge. Larger rivals have deeper clinical experience and more resources to bring bone therapies through late-stage trials and into the market.
The signal: The round highlights continued investor appetite for biotech companies with defined targets and upcoming clinical milestones. Even as venture funding stays selective, capital is still flowing to drug developers with credible science and clear trial paths.
It also underscores growing interest in diseases tied to ageing and chronic metabolic conditions, where demand for better treatments is expected to rise over the coming decade.
Sources:
Angitia Biopharmaceuticals
Fierce Biotech
Globe Newswire
BioSpace
Marketscreener
BioCentury
J.V.
